Portfolio Receipts of $742 million in Q4 2024 and $2,801 million for FY 2024Royalty Receipts growth of 12% in Q4 2024 and 13% for FY 2024 Net ...

Portfolio Receipts of $742 million in Q4 2024 and $2,801 million for FY 2024Royalty Receipts growth of 12% in Q4 2024 and 13% for FY 2024 Net cash provided by operating activities of $743 million in ...

Despite promising Phase 3 results, safety concerns, namely liver injury, have impacted Agios stock and could affect Pyrukund's approval and market adoption. Read the full report here.

Agios Pharmaceuticals Inc (AGIO) reports a 51% increase in net Pyrukynd revenue and outlines promising future launches and ...

Detailed price information for Agios Pharmaceuticals (AGIO-Q) from The Globe and Mail including charting and trades.

We recently compiled a list of the 10 Cheap Biotech Stocks to Invest in Now. In this article, we are going to take a look at ...

We think the strategy to find more effective combination therapies in hematology and build a larger oncology and dermatology portfolio is solid, although we're waiting for key data before assuming the ...

Red blood cell hemoglobin and oxygen molecule dissolve Red blood cell dissolving with hemoglobin and oxygen molecules on both white and black background — concept anemia diagram stock videos & royalty ...

Find Anemia Patient stock video, 4K footage, and other HD footage from iStock. Get higher quality Anemia Patient content, for less—All of our 4K video clips are the same price as HD. Video Back Videos ...

Zydus will set its own prices for the generic product, paying a royalty on sales to Gilead to ... inhibitor (HIF-PHI), as a treatment for anemia associated with Chronic Kidney Disease (CKD).

Detailed price information for Agios Pharmaceuticals (AGIO-Q) from The Globe and Mail including charting and trades.

Incyte Reports 2024 Fourth Quarter and Year-End Financial Results, Provides 2025 Financial Guidance and Highlights 2025 R&D ...